Pulmonary Arterial Hypertension - Winrevair Prior Authorization Policy
Prior authorization coverage policy for Winrevair (sotatercept-csrk) for treatment of pulmonary arterial hypertension (WHO Group 1) in adults, including initiation and continuation criteria, documentation requirements, prescriber specialty requirement, duration of approval, and non-covered uses.
Functional Class IV was added to the required functional class list (previously only II and III).
Documentation examples 'prescription claims records and prescription receipts' were added as acceptable documentation.
Added 'Documentation required' language to criteria regarding patients receiving at least two other PAH therapies or receiving at least one other PAH therapy and intolerant to combination therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.